Conditioning Regimen A + Conditioning Regimen B + Conditioning Regimen C + Conditioning Regimen D + Conditioning Regimen E + PTCy (50 mg/kg D3, D4) + PTCy (25 mg/kg D3, D4) + Post-transplant Tacrolimus + Post-transplant Mycophenolate mofetil + Post-transplant Abatacept + Post-transplant Ruxolitinib + Supportive Care: Growth Factors + Supportive Care: Seizure prophylaxis + Supportive Care: Prophylaxis against infections
Phase 2RecruitingDevelopment Stage
AML (Acute Myelogenous Leukemia)
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Jul 25, 2025 → Jun 1, 2028
About Conditioning Regimen A + Conditioning Regimen B + Conditioning Regimen C + Conditioning Regimen D + Conditioning Regimen E + PTCy (50 mg/kg D3, D4) + PTCy (25 mg/kg D3, D4) + Post-transplant Tacrolimus + Post-transplant Mycophenolate mofetil + Post-transplant Abatacept + Post-transplant Ruxolitinib + Supportive Care: Growth Factors + Supportive Care: Seizure prophylaxis + Supportive Care: Prophylaxis against infections
Conditioning Regimen A + Conditioning Regimen B + Conditioning Regimen C + Conditioning Regimen D + Conditioning Regimen E + PTCy (50 mg/kg D3, D4) + PTCy (25 mg/kg D3, D4) + Post-transplant Tacrolimus + Post-transplant Mycophenolate mofetil + Post-transplant Abatacept + Post-transplant Ruxolitinib + Supportive Care: Growth Factors + Supportive Care: Seizure prophylaxis + Supportive Care: Prophylaxis against infections is a phase 2 stage product being developed by Incyte for AML (Acute Myelogenous Leukemia). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06859424. Target conditions include AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category).
What happened to similar drugs?
1 of 1 similar drugs in AML (Acute Myelogenous Leukemia) were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06859424 | Phase 2 | Recruiting |
Competing Products
6 competing products in AML (Acute Myelogenous Leukemia)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Gilteritinib + Venetoclax + Azacitidine (AZA) + Local standard of care (SOC) | Astellas Pharma | Phase 2/3 | 45 |
| ticagrelor 90 mg | AstraZeneca | Pre-clinical | 26 |
| Roflumilast + Placebo | AstraZeneca | Phase 2 | 27 |
| milatuzumab | Gilead Sciences | Phase 1 | 21 |
| Olutasidenib + CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates | Rigel Pharmaceuticals | Approved | 44 |
| p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine | Inovio Pharmaceuticals | Phase 2 | 25 |